A new clinical trial reports that THC can reduce pain and strengthen a specific brain-driven pain-filtering mechanism in people with fibromyalgia, offering insight into how marijuana may help patients with central sensitization disorders.
The randomized, double-blind, placebo-controlled crossover study, conducted by researchers at Tel Aviv University, enrolled 23 women with fibromyalgia and tested how a single sublingual dose of THC-rich oil affected two well-established markers of central pain modulation: offset analgesia (OA) and conditioned pain modulation (CPM). OA reflects the brain’s ability to sharply down-regulate pain in response to a tiny reduction in a noxious stimulus, while CPM measures how one painful stimulus can dampen another.
Participants completed pain questionnaires and underwent thermal pain-testing procedures before and after receiving either THC at 0.2 mg/kg or a placebo. According to the researchers, THC significantly reduced patients’ spontaneous pain scores on the McGill Pain Questionnaire compared to both baseline and placebo.
The most notable finding was THC’s effect on offset analgesia. The compound consistently strengthened OA responses, indicating improved top-down pain control. No similar effect was found for CPM, which relies more heavily on brainstem pathways than cortical circuits. The study suggests THC may preferentially influence higher-order pain-regulation systems involved in attention, expectation, and emotional processing.
Baseline OA also proved to be an important predictor: patients with stronger OA before treatment experienced greater pain relief after THC. CPM showed no such relationship. That makes this the first study to indicate that OA may help identify fibromyalgia patients who are more likely to respond to THC-based treatments.
Side effects with THC were generally mild and non-severe, and no significant effects were reported in the placebo condition.
The authors say the findings reinforce the idea that THC can modulate central pain pathways in ways that differ from other analgesics. While CPM was unaffected, the improvement in OA points to selective engagement of cortical networks known to be disrupted in fibromyalgia. The results also highlight the potential of OA as a clinical biomarker to guide personalized cannabinoid therapy for chronic pain.
More articles from The Marijuana Herald can be found below.
